Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
Key Information
Due Date: June 2, 2025
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: Not Specified
Funding Type: Grant
Match Required: No
Contact Info:
grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
The types of therapeutic agents can range from small molecules, biologics, to biotechnology-derived products. Moreover, this funding opportunity also caters to pharmacodynamic and pharmacokinetic studies that accompany the preclinical efficacy studies.
One of the primary objectives of this NOFO is to stimulate the development of therapies for rare diseases by advancing pertinent projects. This would be achieved when these projects reach a point where they draw further investment, which would then support the full development of an Investigational New Drug (IND) application. Alternatively, it could also lead to its progression to clinical trials, especially when it comes to repurposing or repositioning.
Key Dates
Open Date: July 5, 2023
Application Due Date: June 2, 2025
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses